StockNews.AI
CASI
StockNews.AI
3 hrs

CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial Results

1. CASI reported financial results for Q2 2025, emphasizing its CID-103 program. 2. The CID-103 program could be a leading treatment in its class.

Earnings
0%Current Return
VS
0%S&P 500
$2.3108/29 04:07 PM EDTEvent Start
$2.3108/29 06:33 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

CASI's focus on CID-103 may enhance investor confidence, mirroring past successes with innovative therapies.

How important is it?

The article highlights a significant clinical focus which is key for future growth and valuation.

Why Long Term?

The advancements in the CID-103 program could lead to significant future revenue streams.

Related Companies

VRTXGILDREGN
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today reported business and financial results for the quarter ended June 30, 2025 (the "second quarter"). "We are focused on advancing our CID-103 program, a potentially best-in-class anti-CD38 monoclonal antibody," said David Cory, CEO of CASI.

Related News